Home › Research › Biomarkers
Menopausal vasomotor symptoms and plasma Alzheimer disease biomarkers
Thurston RC, Maki P, Chang Y, Wu M, Aizenstein HJ, Derby CA, Karikari TK.. American journal of obstetrics and gynecology, 2023-11-07
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Background Identifying risk factors for Alzheimer disease in women is important as women compose two-thirds of individuals with Alzheimer disease. Previous work links vasomotor symptoms, the cardinal menopausal symptom, with poor memory performance and alterations in brain structure, function, and connectivity. These associations are evident when vasomotor symptoms are monitored objectively with ambulatory skin conductance monitors. Objective This study aimed to determine whether vasomotor symptoms are associated with Alzheimer disease biomarkers. Study design Between 2017 and 2020, the MsBrain study enrolled 274 community-dwelling women aged 45 to 67 years who had a uterus and at least 1 ovary and were late perimenopausal or postmenopausal status. The key exclusion criteria included neurologic disorder, surgical menopause, and recent use of hormonal or nonhormonal vasomotor symptom treatment. Women underwent 24 hours of ambulatory skin conductance monitoring to assess vasomotor symptoms. Plasma concentrations of Alzheimer disease biomarkers, including amyloid β 42-to-amyloid β 40 ratio, phosphorylated tau (181 and 231), glial fibrillary acidic protein, and neurofilament light, were measured using a single-molecule array (Simoa) technology. Associations between vasomotor symptoms and Alzheimer disease biomarkers were assessed via linear regression models adjusted for age, race and ethnicity, education, body mass index, and apolipoprotein E4 status. Additional models adjusted for estradiol and sleep. Results A total of 248 (mean age, 59.06 years; 81% White; 99% postmenopausal status) of enrolled MsBrain participants contributed data. Objectively assessed vasomotor symptoms occurring during sleep were associated with significantly lower amyloid β 42/amyloid β 40, (beta, -.0010 [standard error, .0004]; P=.018; multivariable), suggestive of greater brain amyloid β pathology. The findings remained significant after additional adjustments for estradiol and sleep. Conclusion Nighttime vasomotor symptoms may be a marker of women at risk of Alzheimer disease. It is yet unknown if these associations are causal.
What this study adds
Evidence grade: Low
The record lists 274 participants. In a study of 248 women in late perimenopause or postmenopause, hot flashes occurring during sleep were linked to a lower amyloid β 42/amyloid β 40 ratio in blood, which can suggest more amyloid in the brain. This is an association, not proof that menopausal symptoms cause Alzheimer's disease.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Thurston, R. C., Maki, P., Chang, Y., Wu, M., Aizenstein, H. J., Derby, C. A., et al. (2024). Menopausal vasomotor symptoms and plasma Alzheimer disease biomarkers. American journal of obstetrics and gynecology. https://doi.org/10.1016/j.ajog.2023.11.002
Vancouver
Thurston RC, Maki P, Chang Y, Wu M, Aizenstein HJ, Derby CA, et al. Menopausal vasomotor symptoms and plasma Alzheimer disease biomarkers. American journal of obstetrics and gynecology. 2024. doi:10.1016/j.ajog.2023.11.002. PMID: 37939982.
BibTeX
@article{thurston2024-37939982,
author = {Thurston, R. C. and Maki, P. and Chang, Y. and Wu, M. and Aizenstein, H. J. and Derby, C. A. and Karikari, T. K.},
title = {{Menopausal vasomotor symptoms and plasma Alzheimer disease biomarkers}},
journal = {American journal of obstetrics and gynecology},
year = {2024},
doi = {10.1016/j.ajog.2023.11.002},
pmid = {37939982},
url = {https://doi.org/10.1016/j.ajog.2023.11.002}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- Objective This study aimed to determine whether vasomotor symptoms are associated with Alzheimer disease biomarkers.
- Results A total of 248 (mean age, 59.06 years; 81% White; 99% postmenopausal status) of enrolled MsBrain participants contributed data.
- Objectively assessed vasomotor symptoms occurring during sleep were associated with significantly lower amyloid β 42/amyloid β 40, (beta, -.0010 [standard error, .0004]; P=.018; multivariable), suggestive of greater brain amyloid β pathology.
- The findings remained significant after additional adjustments for estradiol and sleep.
Why it matters
In a study of 248 women in late perimenopause or postmenopause, hot flashes occurring during sleep were linked to a lower amyloid β 42/amyloid β 40 ratio in blood, which can suggest more amyloid in the brain. This is an association, not proof that menopausal symptoms cause Alzheimer's disease.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Participants274
- Evidence strengthLow
How this study scored 50/100
Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (American journal of obstetrics and gynecology) |
| Journal's citation record | 3 / 4 | American Journal of Obstetrics and Gynecology: journal h-index 383 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2024 — within 3 year(s) of the newest study here |
| Sample size | 2 / 4 | 274 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 3 / 7 | Cited 38 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 9.5 citations a year over 4 year(s) since 2024 |
| Impact for its field and year | 3 / 6 | Cited 6.4× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 3 other studies in this library |
| Still being cited | 2 / 4 | Cited 38 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Thomas K. Karikari: h-index 66 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | University of Pittsburgh: institution h-index 1,470 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 3 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 37939982) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 50 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
3 studies in the alzhub library list this one in their references.
Related studies in Biomarkers from nearby years
Also tagged “cerebrospinal”
820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.